GLAUKOS Corp reported the first quarter ended March 31, 2026 results: revenue $150.6 million, net income $19.8 million, EPS ($0.34) per diluted share. Guidance raised.
“of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: • Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. • Glaucoma record net sales of $129.3 million in Q1 2026”
Earnings Releases
GLAUKOS Corp reported first quarter ended March 31, 2024 results: revenue $85.6 million, net income ($40.8 million), EPS ($0.82) per diluted share. Guidance raised.
“of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ● Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. ● Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. ● Corneal Health net sales of $18.4 million in Q1”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.